אקטיבל Israel - hebraisk - Ministry of Health

אקטיבל

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

קיל'ס קרם BB Israel - hebraisk - Ministry of Health

קיל'ס קרם bb

אינטרביוטי קוסמטיקס ישראל בעמ - לחות עם גוון לפנים + הגנה משמש

וילאט 1000 Israel - hebraisk - Ministry of Health

וילאט 1000

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

וילאט 500 Israel - hebraisk - Ministry of Health

וילאט 500

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

סנדוסטטין 30 מג LAR Israel - hebraisk - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR Israel - hebraisk - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.